| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Luba Yammine, Jessica C Balderas, Michael F Weaver, Joy M Schmit. Feasibility of Exenatide, a GLP-1R Agonist, for Treating Cocaine Use Disorder: A Case Series Study. Journal of addiction medicine. vol 17. issue 4. 2023-08-14. PMID:37579116. |
no medications have yet been proven to be effective for the treatment of cocaine use disorder (cud). |
2023-08-14 |
2023-09-07 |
human |
| Eleanor Blair Towers, Ivy L Williams, Emaan I Qillawala, Wendy J Lync. Role of nucleus accumbens dopamine 2 receptors in motivating cocaine use in male and female rats prior to and following the development of an addiction-like phenotype. Frontiers in pharmacology. vol 14. 2023-08-11. PMID:37564182. |
a hallmark of cocaine use disorder (cud) is dysfunction of dopamine signaling in the mesolimbic pathway, including impaired dopamine 2 (d2) receptor signaling. |
2023-08-11 |
2023-08-16 |
human |
| Susana Barbosa-Méndez, Alberto Salazar-Juáre. Estradiol enhances the mirtazapine effects on the expression of cocaine-induced locomotor sensitization in female rats. Behavioural pharmacology. vol 34. issue 6. 2023-08-02. PMID:37530137. |
epidemiological studies have mentioned that cocaine use disorder (cud) has increased in the last decade among women; these show endocrine and reproductive disorders and a high propensity to stress and depression disorders. |
2023-08-02 |
2023-08-14 |
rat |
| Samara Vilca, Claes Wahlestedt, Sari Izenwasser, Raul R Gainetdinov, Marta Pard. Dopamine Transporter Knockout Rats Display Epigenetic Alterations in Response to Cocaine Exposure. Biomolecules. vol 13. issue 7. 2023-07-29. PMID:37509143. |
(1) background: there is an urgent need for effective treatments for cocaine use disorder (cud), and new pharmacological approaches targeting epigenetic mechanisms appear to be promising options for the treatment of this disease. |
2023-07-29 |
2023-08-14 |
rat |
| Britton R Barbee, Shannon L Gourle. Brain systems in cocaine abstinence-induced anxiety-like behavior in rodents: A review. Addiction neuroscience. vol 2. 2023-07-24. PMID:37485439. |
cocaine use disorder (cud) is a significant public health issue that generates substantial personal, familial, and economic burdens. |
2023-07-24 |
2023-08-14 |
mouse |
| María Flores-López, Nuria García-Marchena, Francisco J Pavón-Morón, Nerea Requena-Ocaña, Laura Sánchez-Marín, Laura Martín-Chaves, Mónica García-Medina, Carmen Pedraza, Estela Castilla-Ortega, Juan J Ruiz, Fernando Rodríguez de Fonseca, Pedro Araos, Antonia Serran. Plasma concentrations of lysophosphatidic acid and the expression of its receptors in peripheral blood mononuclear cells are altered in patients with cocaine use disorders. Translational psychiatry. vol 13. issue 1. 2023-06-21. PMID:37344453. |
in order to further explore the potential role of the lpa signaling system as biomarker in cocaine use disorders (cud) we conducted a cross-sectional study with 105 patients diagnosed with cud and 92 healthy controls. |
2023-06-21 |
2023-08-14 |
human |
| Elisabetta Gerace, Simone Baldi, Maya Salimova, Leandro Di Gloria, Lavinia Curini, Virginia Cimino, Giulia Nannini, Edda Russo, Marco Pallecchi, Matteo Ramazzotti, Gianluca Bartolucci, Brunella Occupati, Cecilia Lanzi, Maenia Scarpino, Giovanni Lanzo, Antonello Grippo, Francesco Lolli, Guido Mannaioni, Amedeo Amede. Oral and fecal microbiota perturbance in cocaine users: Can rTMS-induced cocaine abstinence support eubiosis restoration? iScience. vol 26. issue 5. 2023-05-30. PMID:37250301. |
here, we investigated the gut (gm) and oral (om) microbiota composition of cocaine use disorder (cud) patients and the effects of repetitive transcranial magnetic stimulation (rtms). |
2023-05-30 |
2023-08-14 |
Not clear |
| Elisabetta Gerace, Simone Baldi, Maya Salimova, Leandro Di Gloria, Lavinia Curini, Virginia Cimino, Giulia Nannini, Edda Russo, Marco Pallecchi, Matteo Ramazzotti, Gianluca Bartolucci, Brunella Occupati, Cecilia Lanzi, Maenia Scarpino, Giovanni Lanzo, Antonello Grippo, Francesco Lolli, Guido Mannaioni, Amedeo Amede. Oral and fecal microbiota perturbance in cocaine users: Can rTMS-induced cocaine abstinence support eubiosis restoration? iScience. vol 26. issue 5. 2023-05-30. PMID:37250301. |
in conclusion, cud patients showed a profound dysbiotic fecal and oral microbiota composition and function and rtms-induced cocaine abstinence determined the restoration of eubiotic microbiota. |
2023-05-30 |
2023-08-14 |
Not clear |
| Kanhao Zhao, Gregory A Fonzo, Hua Xie, Desmond J Oathes, Corey J Keller, Nancy Carlisle, Amit Etkin, Eduardo A Garza-Villarreal, Yu Zhan. A generalizable functional connectivity signature characterizes brain dysfunction and links to rTMS treatment response in cocaine use disorder. medRxiv : the preprint server for health sciences. 2023-05-10. PMID:37162878. |
cocaine use disorder (cud) is a prevalent substance abuse disorder, and repetitive transcranial magnetic stimulation (rtms) has shown potential in reducing cocaine cravings. |
2023-05-10 |
2023-08-14 |
Not clear |
| Anna-Chiara Schaub, Marc Vogel, Undine E Lang, Stefan Kaiser, Marc Walter, Marcus Herdener, Johannes Wrege, Matthias Kirschner, André Schmid. Transdiagnostic brain correlates of self-reported trait impulsivity: A dimensional structure-symptom investigation. NeuroImage. Clinical. vol 38. 2023-05-03. PMID:37137256. |
structural magnetic resonance imaging (smri) datasets from 234 participants including hcs (n = 109) and patients with opioid use disorder (oud, n = 22), cocaine use disorder (cud, n = 43), borderline personality disorder (bpd, n = 45) and schizophrenia (sz, n = 15) were included. |
2023-05-03 |
2023-08-14 |
human |
| Vitor S Tardelli, Lais F Berro, Gilberto Gerra, Leonardo Tadonio, Adam Bisaga, Thiago M Fidalg. Prescription psychostimulants for cocaine use disorder: A review from molecular basis to clinical approach. Addiction biology. vol 28. issue 4. 2023-04-05. PMID:37016755. |
prescription psychostimulants (pps) could be useful to treat cocaine use disorder (cud) as they share the pharmacological effects with cocaine, as evidenced by a recent meta-analysis that assessed 38 randomized clinical trials (rcts). |
2023-04-05 |
2023-08-14 |
Not clear |
| Bernard N Johnson, Mia I Allen, Beth A Reboussin, Christina LaValley, Michael A Nade. Delay discounting as a behavioral phenotype associated with social rank in female and male cynomolgus monkeys: Correlation with kappa opioid receptor availability. Pharmacology, biochemistry, and behavior. 2023-04-02. PMID:37004977. |
cocaine use disorder (cud) is a significant problem worldwide, with no fda-approved treatments. |
2023-04-02 |
2023-08-14 |
monkey |
| Bernard N Johnson, Mia I Allen, Beth A Reboussin, Christina LaValley, Michael A Nade. Delay discounting as a behavioral phenotype associated with social rank in female and male cynomolgus monkeys: Correlation with kappa opioid receptor availability. Pharmacology, biochemistry, and behavior. 2023-04-02. PMID:37004977. |
epidemiological data indicate that only about 17 % of people that use cocaine will meet dsm criteria for cud. |
2023-04-02 |
2023-08-14 |
monkey |
| Núria Mallorquí-Bagué, Alba Palazón-Llecha, Mercè Madre, Francesca Batlle, Santiago Duran-Sindreu, Joan Trujol. CBT4CBT web-based add-on treatment for cocaine use disorder: Study protocol for a randomized controlled trial. Frontiers in psychiatry. vol 14. 2023-03-20. PMID:36937712. |
cocaine use disorder (cud) is a chronic condition that presents high relapse rates and treatment dropouts. |
2023-03-20 |
2023-08-14 |
Not clear |
| Jake Schechter, Geoffrey W Brown, Maria Jand. A preliminary evaluation of N-acetylcysteine's effects on patient adherence to treatment for cocaine use disorder. The mental health clinician. vol 13. issue 1. 2023-03-09. PMID:36891481. |
cocaine use disorder (cud) is a disabling disease associated with high rates of relapse and intense cravings. |
2023-03-09 |
2023-08-14 |
Not clear |
| Jaqueline B Schuch, Natália Becker, Francisco Diego Rabelo-da-Ponte, Felipe Ornell, Hellen J M Freitas, Fernando P Rebelatto, Anne O Sordi, Flavio Pechansky, Lisia von Diemen, Felix H P Kessle. Assessment of cognitive functioning using the Mini Mental State Examination in men with Alcohol and Crack Cocaine Use Disorder. Trends in psychiatry and psychotherapy. 2023-03-08. PMID:36889679. |
our aim was to evaluate the cognitive performance of individuals with alcohol and/or crack cocaine use disorder (aud, cud, and polysubstance use) using the mmse, and to investigate the impact of substance use profile, and the moderation effect of educational level on mmse performance. |
2023-03-08 |
2023-08-14 |
Not clear |
| Eric Poisel, Lea Zillich, Fabian Streit, Josef Frank, Marion M Friske, Jerome C Foo, Naguib Mechawar, Gustavo Turecki, Anita C Hansson, Markus M Nöthen, Marcella Rietschel, Rainer Spanagel, Stephanie H Wit. DNA methylation in cocaine use disorder-An epigenome-wide approach in the human prefrontal cortex. Frontiers in psychiatry. vol 14. 2023-03-03. PMID:36865068. |
cocaine use disorder (cud) is characterized by a loss of control over cocaine intake and is associated with structural, functional, and molecular alterations in the human brain. |
2023-03-03 |
2023-08-14 |
human |
| Giselle A Funchal, Jaqueline B Schuch, Aline Zaparte, Breno Sanvicente-Vieira, Thiago W Viola, Rodrigo Grassi-Oliveira, Moisés E Baue. COCAINE USE DISORDER AND CHILDHOOD MALTREATMENT ARE ASSOCIATED WITH THE ACTIVATION OF NEUTROPHILS AND INCREASED INFLAMMATION. Acta neuropsychiatrica. 2023-02-27. PMID:36847141. |
cocaine use disorder (cud) has been associated with early life adversity and activated cellular immune responses. |
2023-02-27 |
2023-08-14 |
Not clear |
| Brian Sabato, Paulo Sérgio de Almeida Augusto, Raissa Lima Gonçalves Pereira, Felipe Coutinho Batista Esteves, Sordaini M Caligiorne, Bruna Rodrigues Dias Assis, Sóstenes Apolo Correia Marcelino, Larissa Pires do Espírito Santo, Karine Dias Dos Reis, Leonardo Da Silva Neto, Gisele Goulart, Ângelo de Fátima, Felipe Pierezan, Ricardo Toshio Fujiwara, Maila Castro, Frederico Garci. Safety and immunogenicity of the anti-cocaine vaccine UFMG-VAC-V4N2 in a non-human primate model. Vaccine. 2023-02-23. PMID:36822966. |
our research group developed a new vaccine candidate, the ufmg-v4n2, to treat cocaine use disorders (cud) using an innovative carrier based on calixarenes. |
2023-02-23 |
2023-08-14 |
Not clear |
| Luba Yammine, Jessica C Balderas, Michael F Weaver, Joy M Schmit. Feasibility of Exenatide, a GLP-1R Agonist, for Treating Cocaine Use Disorder: A Case Series Study. Journal of addiction medicine. 2023-02-17. PMID:36799773. |
no medications have yet been proven to be effective for the treatment of cocaine use disorder (cud). |
2023-02-17 |
2023-08-14 |
human |